Subepithelial lesions (SLEs) are often detected incidentally during endoscopic examination. They represent a heterogeneous ...

A noteworthy case study. What caused a 43-year-old woman to develop lesions all over her body that were not only extremely ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

In this study, we aimed to identify the role of immune infiltration in pancreatic neuroendocrine tumors (Pan-NETs ... patients diagnosed with Pan-NET G3 (well differentiated in histology, with Ki-67 ...

In pathology, oncocytic change is a proliferation ... that distinguishes these tumors from other calcitonin-expressing neuroendocrine neoplasms. Little is known about the molecular alterations that ...

Based on the imaging findings, the patient was taken to the operating room for resection of what was presumed to be a metastatic neuroendocrine tumour. However ... report highlights that ...

III and IV), tumour size (codes: 5-988), therapy; surgery of the primary site for patients with stage I and stage II disease (codes: 0-90). We excluded cases with variant histology such as those with ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

You might also hear them called lung neuroendocrine neoplasms (NENs). This means the same as neuroendocrine cancer. There are 2 key groups of lung neuroendocrine cancer: lung neuroendocrine tumours ...

Your healthcare team might call them stomach neuroendocrine neoplasms (stomach NENs). But neuroendocrine cancer and neuroendocrine neoplasm mean the same thing. Read more about the difference between ...

This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...